Evaluating Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy Versus Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer: A Prospective, Randomized Controlled Phase II Clinical Trial
Latest Information Update: 23 Nov 2022
At a glance
- Drugs Catequentinib (Primary) ; Cisplatin; Docetaxel; Tislelizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Nov 2022 Status changed from recruiting to discontinued.
- 08 Aug 2022 New trial record